Addressing the Key Challenges of Decentralized Clinical Trials in Europe: Multistakeholder Perspective Delphi Study
Journal of Medical Internet Research · 09.07.2026 · 28 · e80625-e80625
DOI: 10.2196/80625 ↗Kurz gefasst
Delphi-Studie in der Zeitschrift Journal of Medical Internet Research, online erschienen am 09.07.2026. Verfasst von Carlos Murciano-Gamborino und 8 weiteren Autor:innen. Beteiligte Einrichtung: Vaccines Research Area, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO-Public Health), Avenida Catal…. Hauptthemen laut MEDLINE: Clinical Trials as Topic. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Decentralized clinical trials (DCTs) represent an emerging model in clinical research, accelerated by the restrictions imposed during the COVID-19 pandemic. By leveraging digital technologies and local health care resources, DCTs aim to increase accessibility and reduce participant burden compared to traditional site-based models, which often face recruitment failures and high attrition rates. While various regulatory initiatives in Europe, such as the Accelerating Clinical Trials in the European Union program and the European Medicines Regulatory Network recommendation paper (updated in October 2025), have sought to facilitate their implementation, the widespread adoption of DCTs remains limited due to significant operational, regulatory, and technological challenges, including platform fragmentation and gaps in digital literacy.
Objective
This study aimed to identify and prioritize actionable solutions to the main challenges of DCT implementation in Europe from a multistakeholder perspective, gathering insights to address specific ethical, legal, and operational barriers.
Methods
Building on a preceding strengths, weaknesses, opportunities, and threats analysis, a 2-round Delphi study was conducted, involving 26 experts in clinical trials, ethics, law, regulation, and patient engagement between March and May 2023. In the first round, 309 open-ended responses were collected via REDCap (Research Electronic Data Capture; Vanderbilt University) surveys and underwent systematic inductive content analysis using ATLAS.ti (ATLAS.ti Scientific Software Development GmbH) with independent double coding. This process resulted in 244 unique proposals that were categorized according to 6 key challenges. In the second round, 39 synthesized proposals were evaluated using a 4-point Likert scale. Consensus was defined as ≥80% agreement on the appropriateness of each proposal.
Results
High levels of consensus were achieved, with 32 out of the 39 proposals reaching the threshold and 14 achieving 100% unanimity. Overall, 82% of the proposals were rated as “appropriate” or “very appropriate.” Key recommendations included providing support and training for health care professionals, enhancing investigational medicinal product and biological sample logistics through validated technologies, improving collaboration with local health care providers, fostering regulatory harmonization while respecting national specificities, strengthening capacity-building initiatives, and promoting accessible, user-friendly digital tools supported by hybrid trial models. Conversely, proposals such as peer-to-peer participant support and the centralization of ethics reviews at the European Union level failed to reach consensus.
Conclusions
The study offers a prioritized compilation of expert-driven recommendations for overcoming current barriers to DCT implementation in Europe. The adoption of these recommendations could support the development of more inclusive, efficient, and sustainable decentralized research frameworks across diverse health care systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Vaccines Research Area, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO-Public Health), Avenida Cataluña, 21, Valencia, 46020, Spain, 34 961925948.
- Biomedical Research Networking Center for Epidemiology and Public Health (CIBERESP), ISCIII, Madrid, Spain.
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
- Rotterdam University of Applied Sciences, Rotterdam, The Netherlands.
- Pfizer R&D UK Limited, Walton-on-the-Hill, United Kingdom.
- UCB Biopharma, Brussels, Belgium.
Zitieren
APA
Murciano-Gamborino, C., Pérez-Breva, L., de Jong, A. J., Boeckhout, M., van Thiel, G. J. M. W., Huntley, K., Traore, H., Gardarsdottir, H., & Fons-Martinez, J. (2026). Addressing the Key Challenges of Decentralized Clinical Trials in Europe: Multistakeholder Perspective Delphi Study. Journal of Medical Internet Research, 28, e80625-e80625. https://doi.org/10.2196/80625
Vancouver
Murciano-Gamborino C, Pérez-Breva L, de Jong AJ, Boeckhout M, van Thiel GJMW, Huntley K, et al. Addressing the Key Challenges of Decentralized Clinical Trials in Europe: Multistakeholder Perspective Delphi Study. Journal of Medical Internet Research. 2026;28:e80625-e80625. doi:10.2196/80625
BibTeX
@article{MurcianoGamborino2026,
author = {Murciano-Gamborino, Carlos and Pérez-Breva, Lina and de Jong, Amos J and Boeckhout, Martin and van Thiel, Ghislaine Jose Madeleine Wilhelmien and Huntley, Kate and Traore, Hamidou and Gardarsdottir, Helga and Fons-Martinez, Jaime},
title = {Addressing the Key Challenges of Decentralized Clinical Trials in Europe: Multistakeholder Perspective Delphi Study},
journal = {Journal of Medical Internet Research},
year = {2026},
volume = {28},
pages = {e80625--e80625},
doi = {10.2196/80625}
}
EUVIMED